Insight Molecular Diagnostics Inc. entered into a registered direct offering on February 10, 2026, issuing shares and pre-funded warrants to raise approximately $24.5 million in net proceeds, which the company plans to use for general corporate purposes including research and development to expand its GraftAssure product offering.
Key takeaways
The company entered into securities purchase agreements with institutional investors on February 10, 2026.
The offering consisted of 3,482,498 shares of common stock and pre-funded warrants to purchase up to 1,043,478 shares.
The offering price was $5.75 per share and $5.7499 per pre-funded warrant.
Net proceeds from the offering were approximately $24.5 million after deducting placement agent fees and estimated offering expenses.
The company plans to use net proceeds for general corporate purposes, including research and development to expand GraftAssure beyond kidney transplant rejection testing into other organs, most immediately heart transplant rejection testing.
Lake Street Capital Markets, LLC served as placement agent and received fees of 3.0% or 6.0% of gross proceeds depending on investor introduction, plus $125,000 in expense reimbursement.